Health Canada Seizes 11,400 Peptide Vials After Bacteria Found

What Health Canada announced about bacteria in injectable peptides

On November 6, 2026, Global News reported that Health Canada, Canada's federal health regulator, warned consumers after lab testing found three different bacteria that could be harmful to humans in unauthorized peptides sold online¹. The agency seized more than 11,400 vials from Shanghai ERP Peptide Biotechnology Co. Ltd. (ERP Peptide) and from two online retailers that sold its products¹².

The ERP Peptide products named as unauthorized are human chorionic gonadotropin, MOTS-c, NAD+, retatrutide, tesamorelin and tirzepatide¹². Health Canada asked ERP Peptide to stop selling into Canada immediately and is working with the Canada Border Services Agency (CBSA) to stop shipments¹. Another outlet notes it is unclear whether the retailers will face legal consequences².

One caveat matters for a physician audience: neither Global News nor the second outlet we opened names the three bacteria¹², and the full text of the Health Canada advisory was not available to us at publication (the newswire copy returned an access error). We therefore do not identify species or microbial loads, because they are unverified.

Sterility is not the same as purity in an injectable

Much of the gray-market peptide debate centers on purity and dose. Health Canada also lists other risks of untested products: an incorrect amount of active ingredient, unknown ingredients, and contaminants such as solvents, heavy metals, glass or plastic particles and microbes¹. For someone injecting, microbial contamination carries different consequences: the agency says fever, or pain or swelling at the injection site, calls for immediate medical attention¹.

The peer-reviewed literature shows these tests do not substitute for one another. In a 2024 Journal of Medical Internet Research study, three semaglutide vials bought from illegal online pharmacies had no viable microorganisms at the time of testing, yet endotoxin was detected in every sample (2.1645 to 8.9511 EU/mg), and measured semaglutide purity was 7.7% to 14.37% against 99% claimed on the label¹³. A Belgian case report described hemolytic Bacillus cereus in two illegal peptide drugs¹⁵, and a screen of ten falsified peptide drugs in Belgium found purity of 5% to 75% for cysteine-containing peptides, plus arsenic and lead¹⁴.

Our reading, not a conclusion of those studies: a vial can pass one test and fail another, so a purity figure on a label says nothing about sterility.

A pattern of seizures and court orders in Canada

The November announcement continues a series. In April 2025, Health Canada published an advisory on 26 unauthorized injectable peptides seized from Optimum Wellness Centre in Calgary⁷. In August 2025 it seized products from Canada Peptide, with 42 products named in its advisory⁶, and in 2024 it had acted against Quad Inc. in Beloeil, Quebec⁸.

On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research, barring it from manufacturing, testing, distributing, selling and advertising unauthorized injectable peptides; Health Canada announced it on July 29⁴⁵. The April 2026 advisory added that a "For Research Use Only" label does not make a product legal or safe³.

The College of Physicians and Surgeons of Alberta (CPSA) told physicians in April 2026 to ask patients about non-prescribed injectables bought online and to report adverse events to Health Canada⁹. Around the same time, a McMaster University professor warned: "Mark my words, this will absolutely happen — we are going to see serious adverse events"¹⁰.

What it means for physicians in the United States

The case is Canadian, but the supply chain is cross-border. In the US, the interim HHS policy announced in late October 2026 describes enforcement discretion for 503A compounding of six peptides (BPC-157, epitalon, KPV, MOTS-c, semax and TB-500) by physicians, state-licensed pharmacies and federal facilities¹¹. That policy concerns compounding; the Canadian seizure concerned finished vials from an overseas supplier sold online. These are different supply chains and should not be conflated.

The FDA, for its part, issued five warning letters to online peptide vendors on August 24, 2026; every vendor used a "research use only" disclaimer and the agency was not persuaded¹². An expert quoted by Healio summarized: "none of these are approved, and there's still no established dose or long-term safety data for any of them"¹¹.

For clinical practice, Health Canada's message is sober: anyone who has used these products and develops fever, or pain or swelling at the injection site, should seek medical care immediately¹. This article is journalism and regulatory analysis; it does not recommend any human use.